Kidney function may affect new Weight-Loss drug
NCT ID NCT07076030
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new weight-management drug called petrelintide in 39 people with normal or impaired kidney function. Researchers wanted to see if kidney problems change how the drug behaves in the body. The goal is to guide safe dosing for people with kidney issues who might use this drug for weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- petrelintide (ZP8396)
- What this could lead to
- If successful, this study could help doctors understand how to dose petrelintide safely in people with kidney problems.
- What could go wrong
- This is a very early Phase 1 study with only 39 people, so results may not apply to everyone. It only looks at drug levels in the blood, not weight loss or long-term safety.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Research Organisation GmbH
Berlin, 10117, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Kidney function may change how D-2570 works in the body
- Sleep drug YZJ-1139 put to the test in kidney patients
- Kidney function may change how antibiotic levornidazole acts in the body
- Kidney health may change how this drug works
- Kidney function may change how VC005 drug works
- New drug INCB123667 tested in kidney patients for safety